Thank you for the transfer of your research manuscript to EMBO reports. We have now received the enclosed reports on it. As you will see, the referees acknowledge that the results are potentially intersting and novel. However, they also suggest a few more experiments to strengthen the study, and given the overall number and nature of the concerns, I think that all of them can and should be addressed.
We would thus like to invite you to revise your manuscript with the understanding that the referee concerns must be fully addressed and their suggestions taken on board. Please address all referee concerns in a complete point-by-point response. Acceptance of the manuscript will depend on a positive outcome of a second round of review. It is EMBO reports policy to allow a single round of revision only and acceptance or rejection of the manuscript will therefore depend on the completeness of your responses included in the next, final version of the manuscript.
REFEREE REPORTS ----------------------------

Referee #1:
The manuscript by Grochowska et al. investigates the role of the Aβ3(pE)-42 isoform on synaptic dysfunction. They found that Aβ3(pE)-42, unlike Ab1-42, induces TNFa in astrocytes associated with synaptic dysfunction. This synaptic dysfunction was independent of NMDAR signaling. The manuscript includes important results, which show that Aβ3(pE)-42 plaus an important role in neuroinflammatory processes and pathogenesis of AD. However there are several points the authors should address to improve their work.
Major comments:
1. It is not clear whether the experiment for LTP recording of the effect of Ab1-42 and Ab3(pE)-42 shown in Fig. 3B ,C was performed in the same experiment with D1/D5 receptor agonist shown in Fig. 3G ,H, as both shown in separate panels. The experimental groups should be performed and shown in the same experiment/panels similarly to Fig. 3I . Otherwise, the authors should clearly state it. 2. Did the authors check the presence of microglia in their primary culture? What is the role of Aβ3(pE)-42 on microglia and their contribution to synaptic dysfunction if the primary culture is contaminated and microglia proliferate in cultures treated with Ab3(pE)-42? 3. The authors show significant increase in Iba+ microglial signal in organotypic hippocampal slices treated with Ab3(pE)-42. From Figure S3B its not clear whether Ab3(pE)-42 induced microglia activation or proliferation. Nuclear (DAPI) quantification should be provided. The authors should assess the effect of Ab3(pE)-42 on microglia proliferation (i.e. BrdU incorporation). 4. The authors stated that hippocampal primary cultures revealed negative Iba1+ signal. Thus, they concluded that astrocytes were the source for TNFa. This is unlikely, as microglia present in the hippocampus. 5. The major discovery of this study is the role of Aβ3(pE)-42, unlike Ab1-42, on induction of TNFa in astrocytes associated with synaptic dysfunction. The authors should carefully examine the effect of Ab3(pE)-42 on astrocytes and microglia. They can implement several widely used today approaches to pharmacologically or genetically deplete microglia in primary cells or hippocampal cultures to address whether by Ab3(pE)-42-induced synaptic dysfunctions is mediated by astrocytes or microglia or both. Moreover, the authors can specifically deplete TNFa in microglia using recently described technique (CX3CR1(cre) /TNFα(fl/fl): PMID: 27145902) or use global TNFa-KO mice donors for primary culture or OHSCs. 6. The authors used anti-TNFa neutralizing antibody. The authors did not show the specificity and efficacy of these antibodies i.e. competition assay.
Minor comments:
1. Results section should describe the results in the figures, other references should be for the discussion section 2. Methods: Authors should state n numbers, sex and ages in the methods section to clarify for readers. 3. Figure 1 : Legend is mismatch for I and K letters of the correspondent panels. 4. Figure 2 : This figure needs to be re-organised. Change location of E,F to G,H to reflect it in the result section. Legend needs to be re-organised: instead listing A, C, E, and G, describe each panel in consecutive order. Authors should take care when describing the figure legends so as it corresponds to what is in the figure. 5. Avert to use "stark contrast", just say "in contrast". 6. Authors should carefully scan text for grammatical and spelling errors. There are several mistakes within the manuscript.
Referee #2:
In the manuscript entitled « Posttranslational modification impact on the mechanism by which amyloid-β induces synaptic dysfunction » investigate the molecular mechanisms involved in the synaptic dysfunction. For this purpose they studied multiples parameters of synaptic activity exposed to the same concentration of oligomers of Human Aβ 1-42 and Aβ 3(pE)-42. Overall, they described that if both species triggered synaptic dysfunction, they exert their synaptotoxic effect through a completely different molecular mechanisms. These results are interesting and raise questions that should be addressed: Page 6 result section: How long the cultures have been exposed to the different oligomers species to induce synaptic loss? (It seems to be 3 days as mentioned in the method section). This point should be mentioned clearly in the result section. Is the difference in synapse loss observed after treatment with the different species of oligomers really drastically different (as mentioned in the text) since the difference (in fig 1) between these two conditions seems to be rather small? Is the drastic reduction in synapse density reversed by TNF-α antibody or mimicked by TNF-α? These points should be clarified. Page 10: The decrease in spontaneous neuronal network activity is obtained after a 40 min exposure to both oligomeric species and retraction of synaptic contact induced by Aβ 1-42 are observed the same time frame (3 days). Is these two important synaptotoxic features related ? is the dendritic retraction observable is reversed by Ifenprodyl incubation?
To further validate that these different species of oligomers are disrupting synaptic function by both activating P38, it will be necessary to show a western blot with the activation pattern of P38 at the key time points of the experiments presented (i.e. 40 min and 3 days)? This would be a great additional figure to further validate P38 as a nodal signaling pathway for both oligomers species.
In the final scheme that summarizes the observations presented in the paper, the authors added phosphorylated tau in the scheme. Do they have specific information on the status of tau after exposure to Aβ 1-42 and Aβ 3(pE)-42?
Referee #3:
While there is widespread, but less than universal agreement that amyloid-β oligomers (AβOs) are potently toxic agents in Alzheimer's disease (AD), relatively scant attention has been paid to the diversity of Aβ species, and the homotypic and heterotypic oligomers that they may form. The present study provides compelling evidence that oligomers made from Aβ1-42 and AβpE3-42 harm neurons by distinct mechanisms. Most notably, in contrast to Aβ1-42 oligomers, Aβ3(pE)-42 oligomers induce early neuronal dysfunction neither by activation of GluN2B-containing NMDA receptors nor by a PrP-dependent mechanism, and their toxicity is mediated by TNFα that is secreted by astrocytes following their apparent uptake of the pyroglutamylated AβOs.
Taken as a whole, the authors make an impressive case that biochemical differences between different Aβ species lead to the formation of funtionally distinct AβOs. This study is arguably one of the most comprehensive demonstrations in support of that idea, and should attract wide interest within the AD research community.
Further attention should be paid to the following significant issues as a prelude to publication. 1) A previous report from several of the present authors showed that AβOs made from AβpE3-42 or coincubated mixtures of AβpE3-42 and Aβ1-42 were potently cytotoxic to neurons at submicromolar concentrations within hours (Nussbaum, et al. Nature 2012). In contrast, the current report states on page 22 (Materials and Methods) that neurons were exposed for up to 3 days to AβpE3-42 oligomers at 500 nM total peptide, but no mention of neuron death under these conditions was mentioned. 2) Figure 5 is somewhat problematic. Most importantly, the claim that astrocytes take up oligomers made from AβpE3-42 or mixtures of AβpE3-42 and Aβ1-42 is not convincing. Although the claim is based on 3D reconstructions of confocal images, the Z-resolution in individual images is ~500 nm, which is likely very similar to the thickness of the astrocyte cytoplasm in the reconstructed images that were provided. In other words, it it possible that the oligomers in question were actually resting on top of the astrocytes, instead if having been internalized. Finally, several minor issues warrant further attention as well. 1) A related study from a different group showed that AβOs made from Aβ1-42 provoke microglia to secrete TNFα that then drives post-mitotic neurons back into the cell cycle, which leads them to die eventually (Bhaskar, et al. Please find enclosed the revised version of the manuscript entitled 'Posttranslational modification impact on the mechanism by which amyloid-induces synaptic dysfunction' (EMBOR-2016-43519V2). We think that we could fully address the criticism of the reviewers and we hope that the paper is now suitable for publication in EMBO Reports. If any questions arise please do not hesitate to contact me.
Point by point response:
We would like to thank the referees for their constructive criticism and their positive comments on the manuscript. In the revised version of the manuscript, we have included several novel experiments to address the suggestions of all three reviewers and we think that the additional data strengthen our observations and conclusions further. We hope that the improved version of the manuscript is suitable for publication in EMBO Reports. Please find below our detailed responses to the raised concerns.
Referee #1:
The Reply: The data presented in the Fig. 3 come from the same experiments -i.e. the slices from C57/B6J mice littermates were treated with the same Aβ preparations with or without the presence of the D1/D5 agonist. For the sake of clarity we have presented the different groups in separate panels since a combined panel would have been overcrowded. We have included a sentence in the figure legend to clarify this issue.
Did the authors check the presence of microglia in their primary culture? What is the role of Ab3(pE)-42 on microglia and their contribution to synaptic dysfunction if the primary culture is contaminated and microglia proliferate in cultures treated with Ab3(pE)-42?
Reply: The preparation protocol for primary cultures includes several steps that are not in favor of microglia attachment. But to address the question we have checked now for the presence of microglia in hippocampal primary cultures before and after treatment with oligomers and we could neither detect microglia by means of immunocytochemistry nor by immunoblotting using Iba1 as a marker. We have included this information in two additional panels in the Figure S2C ,D.
The authors show significant increase in Iba+ microglial signal in organotypic hippocampal slices treated with Ab3(pE)-42. From Figure S3B its not clear whether Ab3(pE)-42 induced microglia activation or proliferation. Nuclear (DAPI) quantification should be provided. The authors should assess the effect of Ab3(pE)-42 on microglia proliferation (i.e. BrdU incorporation).
Reply: In the original manuscript we have already counted the number of Iba-1 positive cells (see EV3). We have also performed a BrdU experiment that did not provide conclusive evidence for an increased proliferation (see picture below). Collectively the results of our experiments point to microglia activation. 
The authors stated that hippocampal primary cultures revealed negative Iba1+ signal. Thus, they
concluded that astrocytes were the source for TNFa. This is unlikely, as microglia present in the hippocampus.
Reply: We have indeed proven that there is no microglia in our culture preparation (see our reply to point 2). Nonetheless the reviewer is obviously right and many reports have clearly shown the importance of microglia-derived TNFα in AD pathology. It is important to note that we don't believe that Aβ3(pE)-42 exclusively induces its synaptotoxic effect via TNFα released from astrocytes. We want to stress that our results do not exclude and actually point to the possibility that microglia as well as astrocytes are important in Ab3(pE)-42-induced synaptic pathology. In our initial experimental design, we used pure, primary astrocytic cultures (the preparation protocol includes a shaking step to remove microglia). In line with previous reports we could show that astrocytes can release TNFα upon treatment with oligomeric preparations (Fig. 7A) . Furthermore, the effect of conditioned media from these cultures treated with Aβ3(pE)-42 can be rescued by prior depletion with TNFα neutralizing antibody ( Fig. 7B-E ) as well as with a TNFR1 antagonist (Fig. EV4) . Finally, we could show that Aβ3(pE)-42 activates not only astrocytes but also microglia in hippocampal organotypic slices. These data, together with the previously mentioned reports, indicate that both astrocytes and microglia contribute to neuroinflammation at the onset of AD. The study how Aβ3(pE)-42 contributes to microglia activation and the consequences of the activation is beyond the scope of the manuscript. We have now included a paragraph clarifying this issue in the Discussion section of the manuscript. Reply: As outlined above there is a major misunderstanding. We don't believe that the effect is specific for astrocytes (and have not stated this in the previous version of the manuscript) and we have included experimental evidence that also microglia is involved in the effects of Aβ3(pE)-42. The main scope of the manuscript is to compare the differential signaling pathways evoked by Aβ1-42 and Aβ3(pE)-42 and we agree that the interplay between microglia and astrocytes is an interesting topic. However, the detailed investigation of the microglia, astrocytic, and neuronal interactions in Aβ1-42-or Aβ3(pE)-42-induced pathology is not within the scope of the manuscript and does not add much to the story at the present stage. The important finding is Aβ3(pE)-42-induced synaptic pathology relies on glial release of TNF-alpha. We think that we could answer the question of the reviewer raised and emphasize now in the Discussion that Ab3(pE)-42-induced synaptic dysfunctions is likely mediated by both astrocytes and microglia.
The major discovery of this
The authors used anti-TNFa neutralizing antibody. The authors did not show the specificity and efficacy of these antibodies i.e. competition assay.
Reply Minor comments:
Results section should describe the results in the figures, other references should be for the discussion section
We have used the references exclusively to introduce the rationale of the experiments, not to discuss the results. We feel that it is easier for the reader to follow for the experimental workflow and would therefore suggest to this reviewer to keep the references in the Reference section.
Methods: Authors should state n numbers, sex and ages in the methods section to clarify for readers.
We have followed the instructions for authors of the Journal and included this information in the Figure legends . Furthermore, the sex and ages of mice used for LTP experiments were already included in materials and methods section .
Figure 1: Legend is mismatch for I and K letters of the correspondent panels.
Figure 2: This figure needs to be re-organised. Change location of E,F to G,H to reflect it in the result section. Legend needs to be re-organised: instead listing A, C, E, and G, describe each panel in consecutive order. Authors should take care when describing the figure legends so as it corresponds to what is in the figure.
5. Avert to use "stark contrast", just say "in contrast".
Authors should carefully scan text for grammatical and spelling errors. There are several mistakes within the manuscript.
Reply to minor comments 3-6: We have corrected the indicated mistakes and provided the missing information.
Referee #2:
In the manuscript entitled "Posttranslational modification impact on the mechanism by which amyloid-β induces synaptic dysfunction" investigate the molecular mechanisms involved in the synaptic dysfunction. For this purpose they studied multiples parameters of synaptic activity exposed to the same concentration of oligomers of Human Aβ 1-42 and Aβ 3(pE)-42. Overall, they described that if both species triggered synaptic dysfunction, they exert their synaptotoxic effect through a completely different molecular mechanisms. These results are interesting and raise questions that should be addressed: Page 6 result section: How long the cultures have been exposed to the different oligomers species to induce synaptic loss? (It seems to be 3 days as mentioned in the method section). This point should be mentioned clearly in the result section. Is the difference in synapse loss observed after treatment with the different species of oligomers really drastically different (as mentioned in the text) since the difference (in fig 1) between these two conditions seems to be rather small?
Reply: The cultures were exposed to the oligomers for 3 days. This information is now included in the results section as well. The p-value by one-way ANOVA between Aβ1-42-and Aβ3(pE)-42-treated group is 0.0617. We have removed the sentence including 'drastically'.
Is the drastic reduction in synapse density reversed by TNF-α antibody or mimicked by TNF-α? These points should be clarified:
Reply: Yes the reduction in synapse-density was prevented by the TNFα neutralizing antibody which was co-applied together with Aβ1-42 or Aβ3(pE)-42 (Fig. 8) . Furthermore, we now performed several experiments demonstrating that application of TNFα causes reductions in synapse density like Aβ3(pE)-42 (EV5A,B). Furthermore, the anti-TNFα antibody was used at a concentration that does not change the number of synapses (Fig. 8A,B) , the levels of pCREB (Fig.  8C,D) , and LTP (Fig. 9B, C) . In conjunction with the results of novel experiments using a TNFR1 peptide antagonist (EV4 A,B) these data demonstrate that Aβ3(pE)-42 induced neuronal dysfunction essentially requires TNFα signaling in neurons
Figure 1: The Scholl analysis reveals an important reduction in dendritic complexity induced by both Aβ 1-42 and Aβ 3(pE)-42. How do the authors explain this effect? Does the same common effector P38 trigger this effect? Is it mimicked by TNF-α? This is a very drastic effect that may have an important role in the physiopathology of both oligomeric species.
Reply: A new set of experiments indicates that the effect is indeed mimicked by TNF-alpha (EV5C).
A rescue experiment with a p38 inhibitor rescued both phenotypes, dendrite retraction and synapse loss after the treatment with TNFα, Aβ1-42 or Aβ3(pE)-42 (EV5 and Fig. S4A-C) .
Page 10: The decrease in spontaneous neuronal network activity is obtained after a 40 min exposure to both oligomeric species and retraction of synaptic contact induced by Aβ 1-42 are observed the same time frame (3 days). Is these two important synaptotoxic features related? is the dendritic retraction observable is reversed by Ifenprodyl incubation?
Reply: We have clarified this in the revised version of the manuscript. The Ca2+ imaging was done 3 days after application. We indeed believe that synaptic retraction might precede dendritic retraction and we indicate this now more clearly in the revised version of the manuscript. We have no conclusive data whether also the dendrite retraction is reversed by ifenprodil. Reply: We have included in the revised version of the manuscript a western blot showing that administration of both Aβ species in cortical primary neurons induces enhanced pP38 levels ( Fig.  S4F-I ).
In the final scheme that summarizes the observations presented in the paper, the authors added phosphorylated tau in the scheme. 2) Figure 5 Reply: In the original micrograph the z resolution was ~250 nm. However, we agree with the reviewer that it is indeed difficult to make this judgement since astrocytes are quite flat. We have included for this reviewer original fluorescence micrographs for this Figure at the end of the rebuttal (see below). For the revision we have also transfected astrocytes with a membrane marker and repeated the experiment (see Fig. 5E ). The original fluorescence micrographs can be also found below. Collectively the data suggest that AβpE3-42 is indeed taken up by astrocytes. 
3) Please include catalog numbers for antibodies and other biological reagents.
Reply: We have included the requested catalog numbers.
4) In figure 4, anti-PrP is mistakenly labeled as anti-PrnP.
Reply: We have corrected this mistake.
5) Fig S6 is mistakenly listed in the text on page 18 as Fig S8.
6) I do not understand Fig 4A.
Reply: Figure 4A represents images from confocal microscope of HEK293T cells transfected with Prp-GFP or GPI-GFP constructs. The cells were treated for 40 min with oligomers, fixed and stained with antibodies detecting oligomers. We observed that there is a significant amount of Aβ1-42 on the surface of cells expressing Prp-GFP but not GPI-GFP. This could not be observed for Aβ3(pE)-42. In addition, we decided to visualize the outline of the cells (marked with a yellow line) based on GFP expression. We have tried to clarify this in the Figure legend.
Fluorescence micrographs for Figure 5D Fluorescence micrographs for figure 5D 2nd Editorial Decision 02 March 2017
Thank you for the submission of your revised manuscript to our journal. We have now received the enclosed reports from the referees that were asked to assess it. Both still have a few more minor comments that I would like you to address before we can proceed with the official acceptance of your manuscript. A few other changes are also needed:
Please move figures S1-S5 with their legends to an Appendix file, and upload this as a single Appendix file.
Although the EMBO reports reference style is numbered, the current format in your manuscript has too many author names. The EMBO reports style is also part of EndNote. Please correct. Please delete the open access statement and paper explained section from the manuscript file.
EMBO press papers are accompanied online by A) a short (1-2 sentences) summary of the findings and their significance, B) 2-3 bullet points highlighting key results and C) a synopsis image that is 550x200-400 pixels large (the height is variable). You can either show a model or key data in the synopsis image. Please note that text needs to be readable at the final size. Please send us this information along with the revised manuscript.
I look forward to seeing a final version of your manuscript as soon as possible.
REFEREE REPORTS ----------------------------
Referee #1:
In the revised version, the authors addressed all reviewer's comments. The manscript is written in a clear and logical way, and the authors used several interesting techniques to support and proof their data.
Minor comment to address:
Referee#1 question 3/ Figure EV3 :
The authors describe an increase in Iba+1 cells, however as they state in the rebuttal letter they could not detect an increase in BrdU+ cells. This should be clarified.
Referee #3:
As reviewer #3 of the prior version of this paper, I am satisfied with the authors' responses to my suggestions for how to improve the manuscript, and I believe that this study will be of substantial interest to Alzheimer's disease researchers. In the course of reading the revised version, however, I did notice the following minor points that deserve further attention and can be adjudicated by the monitoring editor without the need for further input from reviewers.
1) In Fig. 1F , the gray (control) line is barely visible.
2) Similarly, in Fig. 3G , it is difficult to discriminate the clear triangles from the gray triangles.
3) There are numerous minor grammatical errors scattered throughout the text, especially extraneous indefinite articles and prepositions.
2nd Revision -authors' response 13 March 2017
Please find enclosed a revised version of manuscript EMBOR-2016-43519. We made all requested changes and hope that the manuscript is now acceptable for publication in EMBO Reports. Reply to Reviewers' comments:
Referee #1:
Minor comment to address: Referee#1 question 3/ Figure EV3 : The authors describe an increase in
